PERSONETICS
31.1.2023 08:01:43 CET | Business Wire | Press release
Personetics, the global leader in financial data-driven customer engagement for financial services today released a report titled Spotlight On Europe: Banks Need To Nurture Customers’ Financial Well-Being. The report, based on a study conducted by Forrester Consulting on behalf of Personetics, details the opportunities and challenges associated with leveraging money management tools to enhance customer engagement and increase lifetime value.
“Now more than ever, customers demand greater control of their finances and expect their banks to deliver real-time, financial data-driven personalised advice and long-term planning,” said Dorel Blitz, VP of Strategy & Business Development at Personetics. “Yet Forrester’s report reveals that existing Personal Financial Management (PFM) tools are neither meeting customer expectations nor delivering business impact for banks. The banks that will thrive are those which will take advantage of the opportunity to provide advanced and proven money management capabilities.”
Forrester based its conclusions on responses from key banking decision-makers. The report shows that while most banks offer basic PFM and money management capabilities there is a growing, urgent need for both banks and their customers to “evolve their approach in order to successfully raise customers’ levels of financial well-being.”
For example, the European survey revealed disappointingly low levels of customer adoption and engagement with digital money management tools. Although nearly three-quarters (73%) of bankers say they already offers customers some sort of digital money management tool, 77% state that fewer than half of their customers actively use these tools.
The report found that adoption is low because existing money management tools fail to deliver tangible outcomes for customers. Today’s money management tools follow a one-size-fits-all approach, meaning they put too much onus on the end user and fail to help customers achieve their financial goals.
Mr. Blitz added: “The good news is that banks are alive to the issues they face. Now it’s a matter of finding the right path forward, through proactive, hyper-personalised solutions at scale that can make a difference today.”
Below are the core findings across Europe.
Banks have high expectations for money management solutions.
When asked about the benefits of implementing digital technologies for this purpose, the top three benefits were increased customer engagement (47%), increased revenue through upsell and cross-sell (43%) and new customer acquisition (43%).
Traditional PFM fails to deliver effective customer outcomes.
One of the main challenges in deploying these digital capabilities is the absence of an enterprise-wide approach to enhancing customer outcomes. Just over half of banks say they can provide sufficient personalised financial insights and advice based on customers’ financial data. This leaves a significant number of banks without the means to deliver competitive and appealing offers and products for their customers.
A major opportunity exists for innovative banks.
Banks should use an advanced money management platform to deliver business impact, increase revenue, profitability, and customer lifetime value. To do this, financial institutions need to partner with the right vendor and invest in advanced capabilities, adopt a financial data-driven approach, and deliver solutions that customers need when they need them.
Read the full report here.
About Personetics
Personetics is a global financial data-driven personalised customer engagement platform for financial services. The company’s mission is to shape the future of “Self-Driving Finance,” where financial institutions can proactively help consumers improve their financial well-being and achieve financial goals.
Personetics serves more than 100 financial institutions in 32 global markets and reaches 140 million customers. The company is backed by leading venture capital and private equity investors, with offices in New York, London, Tel Aviv, Singapore, Tokyo, Paris, Spain, and Australia.
Learn more at personetics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005691/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
